Clebopride
Based on 1 publication(s) in Google Scholar
Clebopride is an orally active dopamine Receptor antagonist. Clebopride acts on dopamine D2 receptors and has antiemetic and prokinetic effects. Clebopride can be used in the study of functional gastrointestinal disorders.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 55905-53-8
- Formel: C20H24ClN3O2
- Molecular Weight:373.88
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
In Vitro
Clebopride (0.1 nM-10μM, 30 min) selectively binds to D2 dopamine receptors (Ki: 3.5 nM) and α2 adrenergic receptors (Ki: 780 nM) in bovine brain membranes[3].
Clebopride inhibits ETS-induced gastric strip contractions (IC50: 0.43 μM) [3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Parmacokinetics
Chemical Information
-
CAS. Nr. 55905-53-8
-
Molecular Weight 373.88
-
Formel C20H24ClN3O2
-
SMILES
O=C(NC1CCN(CC2=CC=CC=C2)CC1)C3=CC(Cl)=C(N)C=C3OC
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry. [Abstract]2022 Mar 1;34(3):424-440.e7. PMID: 35150639
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 25 mg/mL (66.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Reinheit & Dokumentation
Verweise
[1]. Reis-Carneiro D, et al. Clebopride-Associated Movement Disorders. Mov Disord Clin Pract. 2023 Sep 6;10(10):1562-1563. [Content Brief]
[2]. Elliott PN, et al. Substituted benzamides as cerebral dopamine antagonists in rodents. Neuropharmacology. 1977 May;16(5):333-42. [Content Brief]
[3]. Takeda K, et al. Clebopride enhances contractility of the guinea pig stomach by blocking peripheral D2 dopamine receptor and alpha-2 adrenoceptor. J Pharmacol Exp Ther. 1991 May;257(2):806-11. [Content Brief]
[4]. Segura J, et al. The pharmacokinetics of a new benzamide drug clebopride, in the rat and the dog. J Pharm Pharmacol. 1981 Apr;33(4):214-8. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6747 mL | 13.3733 mL | 26.7465 mL | 66.8664 mL |
| 5 mM | 0.5349 mL | 2.6747 mL | 5.3493 mL | 13.3733 mL | |
| 10 mM | 0.2675 mL | 1.3373 mL | 2.6747 mL | 6.6866 mL | |
| 15 mM | 0.1783 mL | 0.8916 mL | 1.7831 mL | 4.4578 mL | |
| 20 mM | 0.1337 mL | 0.6687 mL | 1.3373 mL | 3.3433 mL | |
| 25 mM | 0.1070 mL | 0.5349 mL | 1.0699 mL | 2.6747 mL | |
| 30 mM | 0.0892 mL | 0.4458 mL | 0.8916 mL | 2.2289 mL | |
| 40 mM | 0.0669 mL | 0.3343 mL | 0.6687 mL | 1.6717 mL | |
| 50 mM | 0.0535 mL | 0.2675 mL | 0.5349 mL | 1.3373 mL | |
| 60 mM | 0.0446 mL | 0.2229 mL | 0.4458 mL | 1.1144 mL |